Both fixed-dose, as-needed aflibercept regimens resolve polypoidal choroidal vasculopathy

Intravitreal aflibercept, given either as needed or on a fixed schedule, improved vision and was well tolerated in patients with polypoidal choroidal vasculopathy, according to a Japanese study.The prospective study included 42 treatment-naïve eyes with polypoidal choroidal vasculopathy. Twenty-five eyes received intravitreal injections of 0.05 mL/2 mg Eylea (aflibercept, Regeneron) every 2 months after three initial monthly doses, and 17 eyes received aflibercept injections on an as-needed basis after three initial monthly doses.

Full Story →